Huo Min, Liu Haiyan, Chen Shaohong, Xiu Lingling, Yu Xue, Zhong Gansheng
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Front Pharmacol. 2025 Apr 28;16:1557717. doi: 10.3389/fphar.2025.1557717. eCollection 2025.
The combination of Liou ex S.B.Ho (kansui) and Fisch (liquorice) is contraindicated in Chinese medicine, but whether it can be used in clinical practice remains controversial. The classic formula, Gansui Banxia decoction (GBD), contains kansui and liquorice, which is effective in treating an abnormal accumulation of body fluids, such as malignant ascites (MA); however, the contraindications of kansui and liquorice have limited its clinical application.
This study aims to provide a theoretical basis for the rational application of kansui-liquorice by investigating its role and mechanism in GBD.
LC-MS/MS was used to detect the metabolic differences of - glycyrrhetinic acid, glycyrrhizic acid, glycyrrhizin, glycyrrhizin, glycyrrhizin terpinolipid A, and paeoniflorin - in the liquid of MA rats before and after taking GBD. Network pharmacology was employed to predict the potential targets and mechanisms of GBD in the treatment of MA. The experimental validation was still using MA rats as a model. Flow cytometry was used to assess the expression of immune cells in blood and ascites, and the proliferation and development of T cells in bone marrow and thymus. Elisa was used to detect the content of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in blood. Western blot and qRT-PCR were used to detect the expression of NPs/NPR-A/cGMP/PKG II pathway-related gene and proteins in kidney. The MA model was established by intraperitoneal injection of walker-256 cells at a concentration of 2 × 106/mL and an injection volume of 1 mL. The model was successfully established when the abdominal cavity was obviously distend and touched with a water-shaking sound, and ascites could be seen after opening the abdominal cavity.
We confirmed that GBD containing kansui-liquorice could promote the metabolism of liquorice and reduce the precipitation of toxic substances (kansuinine A). It may also target cellular immunity to exert a drug effect. Further experimental verification found that GBD containing kansui-liquorice could promote the activation of the NPs/NPRs/cGMP/PKGⅡ pathway and exert a diuretic effect in MA rats. Besides that, it could increase the proportion of CD8CD28 T cells, reduce the proportion of immune-suppressing cells, and maintain the stability of the developmental environment of the T cells.
We believe that kansui and liquorice are important components of GBD, and their combination could promote GBD to promote the clinical remission of MA through direct (activation of the NPs/NPRs/cGMP/PKGⅡ pathway) and indirect (regulating T-cell immunity) water-expelling effects.
中药中,刘(甘遂)和菲施(甘草)的组合是禁忌,但能否用于临床实践仍存在争议。经典方剂甘遂半夏汤(GBD)含有甘遂和甘草,对治疗诸如恶性腹水(MA)等体内津液异常积聚有效;然而,甘遂和甘草的禁忌限制了其临床应用。
本研究旨在通过研究甘遂 - 甘草在甘遂半夏汤中的作用及机制,为其合理应用提供理论依据。
采用液相色谱 - 串联质谱法(LC - MS/MS)检测MA大鼠服用甘遂半夏汤前后腹水中甘草次酸、甘草酸、甘草苷、甘草皂苷、甘草皂苷萜脂质A和芍药苷的代谢差异。运用网络药理学预测甘遂半夏汤治疗MA的潜在靶点和机制。实验验证仍以MA大鼠为模型。采用流式细胞术评估血液和腹水中免疫细胞的表达,以及骨髓和胸腺中T细胞的增殖和发育。酶联免疫吸附测定法(ELISA)检测血液中的心钠素(ANP)和脑钠素(BNP)含量。蛋白质免疫印迹法(Western blot)和实时定量聚合酶链反应(qRT - PCR)检测肾脏中NPs/NPR - A/cGMP/PKG II通路相关基因和蛋白质的表达。通过腹腔注射浓度为2×10⁶/mL、注射体积为1 mL的沃克 - 256细胞建立MA模型。当腹腔明显膨隆,触诊有振水音,打开腹腔可见腹水时,模型成功建立。
我们证实含甘遂 - 甘草的甘遂半夏汤可促进甘草的代谢并减少有毒物质(甘遂宁A)的沉淀。它还可能靶向细胞免疫发挥药物作用。进一步的实验验证发现,含甘遂 - 甘草的甘遂半夏汤可促进NPs/NPRs/cGMP/PKGⅡ通路的激活,并在MA大鼠中发挥利尿作用。除此之外,它可增加CD8CD28 T细胞的比例,降低免疫抑制细胞的比例,并维持T细胞发育环境的稳定性。
我们认为甘遂和甘草是甘遂半夏汤的重要成分,它们的组合可促进甘遂半夏汤通过直接(激活NPs/NPRs/cGMP/PKGⅡ通路)和间接(调节T细胞免疫)的利水作用促进MA的临床缓解。